现在的位置: 首页讲座课堂>正文
GE讲座视频:Cytiva™ hESC Derived Cardiomyocytes for Drug Safet
2013年07月02日 讲座课堂 评论数 1 ⁄ 被围观 3,399+


web_green_graphic[1]

A presentation showing how hESC derived cardiomyocytes can be a powerful approach to assessing cardiac drug liabilities. Nick Thomas describes how hESC derived Cytiva Cardiomyocytes:
• are a valid model of cardiomyocytes from the human heart
• are compatible with assays routinely used for testing cardiotoxicity
• together with high-content assays and analysis, can indicate the mechanism of toxicity of drug compounds
http://www.gelifesciences.com/cardiomyocytes

Cytiva Cardiomyocytes 1E6
Cardiomyocytes are derived from human embryonic stem (hES) cells and could provide a biologically relevant alternative to current cell models and primary cells, for predictive toxicity testing.
Highly characterized: Phenotype characterized by flow cytometry, subcellular imaging, and electrophysiology for both structural and functional markers, such as α-actinin, troponin I, α-MHC and electrical activity.
Functionally verified: Electrical properties verified using patch clamping for both action potential and individual ion channel currents
Representative myocyte population: Comprise ventricular, atrial, and nodal subtypes, the majority being ventricular myocytes.
Scalable: Available in quantities to match a range of applications, from manual patch clamping to high-content screening.
Cryopreserved for ease of use: Stable for at least 6 months when cryopreserved. High cell viability, at least 80%, after thawing. Ready-to- use on thawing, and can be maintained for at least 7 days once recovered into culture.
The availability of more biologically relevant and predictive assays and cell models is key to improving the success rate and reducing the cost of the drug discovery and development process. Such assays and models could facilitate the termination of unpromising compounds earlier in development and the engineering of potential drug molecules to remove toxic liabilities.

In drug discovery and development, up to three quarters of toxicity problems are not detected until preclinical or later stages, and cardiotoxicity is a common cause of drug safety liabilities and withdrawal of drugs during development. Industrial-scale production of cardiomyocytes could provide a readily available supply of cells for safety screening.

相关文档资料请点击下载:

Application Note
High-content analysis of a live multiplexed cytotoxicity study using cardiomyocytes Summary

Explores the utility of GE Healthcare Cardiomyocytes in image-based assays for toxicity screening by describing the results of challenging the cells with a panel of test compounds, including those with known or suspected cardiotoxic liabilities. High-content analysis (HCA) of the results allowed cardiotoxic compounds to be identified and distinguished from each other based on their phenotypic profiles.Close
Brochure
Cytiva Cardiomyocytes Relevant. Reliable. Confident. A new era in safety screening with human cell models Summary

Describes the features and benefits of Cytiva Cardiomyocytes and their application in predictive toxicty testing as a biologically relevant alternative to current cell models and primary cells.Close
IN Cell Analyzer High-Content Cellular Analysis System Summary

Overview of the IN Cell Analyzer High-Content Analysis (HCA) system. Provides featured highlights and configurations of the IN Cell Analyzer 2000 and 6000 instruments and describes IN Cell Investigator image analysis and data visualization software, IN Cell Miner HCM data management platform, and IN Cell Analyzer Compliance Manager software.Close
Join us for the future of predictive toxicity testing.Your vision. Our technologies Summary

Describes the application of IN Cell Analyzer, Investigator, and IN Cell Miner in the imaging and high-content analysis of toxicity assays and its use with human cell models as part of a predicitive toxicolgy program.Close
See what others don’t Deeper insights in drug discovery − better prediction of safety and efficacy Summary

In a world where late-stage failure during drug development can cost over $1 billion, foresight pays. And to see further, you have to look deeper. Drug Discovery Suite is our portfolio of specialist technologies that allows you to achieve deeper insights at every stage of discovery, from target identification to lead optimization. The insights into mechanisms at a molecular as well as cellular level will help you make early predictions of drug safety and efficacy required to rank and select the most promising candidates to take forward.Close
Data File
Cytiva Cell Health and Cell Integrity Assays for high-content analysis Summary

GE Healthcare’s Cytiva Cell Health and Cell Integrity Assay Kits utilize high-content imaging and analysis methodology. They monitor multiple cellular parameters and toxicity indicators to achieve greater sensitivity and information than is possible with single endpoint assays. They are particularly applicable to screening potential drug compounds early in the drug discovery process, but are also suitable for assessing cellular function and processes in cell biology research.Close
Instruction/Protocol
Cytiva Cardiomyocytes User Guide Summary

GE Healthcare Cytiva Cardiomyocytes are human cardiomyocytes derived from the NIH approved stem cell line NIH hESC-10-0061. Cytiva Cardiomyocytes are composed of ventricular, atrial and nodal myocyte sub-populations. They have been extensively characterized and functionally verified by flow cytometry, electrophysiology and sub-cellular imaging for cardiac transcription factor expression, structural markers and individual ion channel activity. Cytiva Cardiomyocytes are supplied cryopreserved in a ready to use format.
oster
Cardiotoxicity - see what others don't Summary

Drug-induced cardiotoxicity can occur through: disruption of essential metabolic and signaling pathways; perturbation of mitochondrial function; loss of cell or organelle membrane integrity; activation of programmed cell death. High-content analysis and Cytiva Cardiomyocytes, an advanced human heart cell model, provide a powerful combination for early detection of key indicators of cardiotoxicity.Close
High content cell profiling as a tool for early drug safety testing using GE Healthcare Cardiomyocytes and IN Cell Analyzer 2000 Summary

During the drug development process, late-stage detection of cardiotoxic side effects can significantly increase program costs and time to market. Failure to detect cardiotoxicity prior to launch can present a serious health risk for patients. Following costly withdrawals of a number of drugs from the market due to unexpected adverse cardiovascular effects, there has been an increased demand for more relevant and readily available cell models for in vitro cardiotoxicity testing. To address this need, GE Healthcare provides differentiated cardiomyocytes derived from human embryonic stem cells. To explore the utility of GE Healthcare Cardiomyocytes in image-based assays for toxicity screening, we challenged the cells with a panel of test compounds, including those with known or suspected cardiotoxic liabilities. High-content analysis (HCA) of the results allowed us to identify cardiotoxic compounds and distinguish them from each other based on their phenotypic profiles.


无觅相关文章插件,快速提升流量

×
腾讯微博